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Abstract
When mammalian tissues are infected by bacteria or fungi, inflammatory cytokines are released that 
cause circulating neutrophils to invade the infected tissue. The cytosolic tyrosine kinase, c-Abl, in these 
tissue neutrophils is activated by TNFα. c-Abl then phosphorylates STAT transcription factors, which 
results in production of the  antiapoptotic protein Mcl-1. The normally short-lived tissue neutrophils 
are then unable to enter apoptosis. c-Abl also causes release of reactive oxygen species (ROS) from 
the mitochondria of the activated neutrophils. These ROS, and ROS generated by NADPH oxidase, 
are bactericidal agents of the innate immune system. In some inflammatory diseases, such as chronic 
obstructive pulmonary disease (COPD), the invading neutrophils become permanently activated, and 
the resulting ROS overproduction causes severe tissue damage. The cyclin-dependent kinase inhibitor, 
seliciclib, blocks transcription through inhibition of cdk9. This results in a relatively rapid decline of 
antiapoptotic Mcl-1 transcripts in activated neutrophils, an increase in neutrophil apoptosis, and less 
ROS leakage and oxidative damage. We present here a model of neutrophil kinetics that simulates the 
principal pathways of c-Abl signalling and  use it to explore possible treatment options for inflammatory 
lung disease.
Introduction
Neutrophils represent the largest population of circulating 
white blood cells, and form an essential component 
of the innate immune system, the primitive form of 
cellular immunity that is believed to have predated the 
development of T cells and B cells in evolution, and 
which remains the first line of defence in mammals. In 
outline, the presence of bacterial cell wall components 
in tissues activates macrophages, which respond by 
releasing inflammatory cytokines. Interleukin 8, in 
particular, attracts neutrophils to the site of infection [1]. 
Another cytokine, tumour necrosis factor alpha (TNFα), 
was shown to be responsible for activation (“priming”) 
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of tissue neutrophils [2]. Neutrophil activation causes 
a number of changes, among which are inhibition of 
spontaneous apoptosis, and stimulation of release from 
mitochondria of reactive oxygen species (ROS). The 
gatekeeper molecule for neutrophil activation is the 
Abelson proto-oncogene (c-Abl), which is activated by 
TNFα [3]. One of the chemokines produced by c-Abl 
is neutrophil-activating peptide-2 (NAP-2, also known 
as CXCL-7) which, as its name suggests, activates 
neutrophils [4].  The c-Abl protein is a cytosolic protein 
tyrosine kinase, which phosphorylates and activates the 
transcription factors STAT3 and STAT5.  These STATs 
drive transcription of the anti-apoptotic proteins Mcl-
1 and Bcl-X
L
, and also of cyclin D1 [4]. STAT3 also 
causes increases in fluxes into the electron transport chain 
(ETC) in mitochondria [5], with commensurate increases 
in electron back-pressure and thus ROS leakage from 
mitochondria.  ROS arise when electrons fall into O2 at 
inappropriate sites of the ETC to produce the superoxide 
anion –O2; the appropriate site on ETC complex IV gives 
O2 4 electrons and 4 protons, thus charging the proton 
gradient while splitting O2 into 2H2O. 
–O2 then becomes 
hydrogen peroxide via superoxide dismutase (SOD) 
which has high activity in neutrophils.  In unactivated 
neutrophils, low baseline levels of peroxide are removed 
by glutathione peroxidase, but in activated neutrophils, 
the capacity of this system is saturated, so that peroxide 
accumulates. This excess hydrogen peroxide then reacts 
with chloride anion to produce hypochlorite, which is 
bactericidal. This reaction is catalysed by the enzyme 
myeloperoxidase. 
Formation of ROS is thus an essential part of the 
elimination of bacterial infection by neutrophils [6], but 
once the infection is eliminated it is essential that the 
activated neutrophils are removed, through apoptosis, 
because prolonged exposure to ROS can cause extensive 
normal tissue damage. If inflammatory cytokines are 
produced chronically, then c-Abl will remain activated, and 
primed tissue neutrophils will continue to produce ROS. 
This appears to be a major contributor to tissue damage 
resulting from inflammatory disease, including chronic 
obstructive pulmonary disease (COPD) [7-10]. COPD is 
the sixth largest cause of death worldwide.  It is associated 
with smoking, and with inhalation of other irritants 
including environmental pollutants. The exact chain of 
events that results in a chronic inflammatory condition 
remains a matter of debate, but is generally attributed 
to inhalation of oxidative free radicals, stimulation of 
inflammatory cytokine production by inhaled irritants, 
and possibly an autoimmune contribution.
The process of neutrophil generation, trafficking, and 
activation is summarised in figure 1, which shows the 
activation of production of Mcl-1 (and thus inhibition 
of neutrophil apoptosis) by c-Abl. The other primary 
consequence of c-Abl activation, production of excessive 
ROS, is shown in more detail in figure 2. Several of the 
processes shown in figures 1 and 2 have been explored 
as targets for development of anti-inflammatory drugs. 
Figure 1. Neutrophil trafficking in the myeloN model. Components enclosed in rectangles are the 19 dynamic system state variables that 
are either cell populations or molecules.  Other components are boundary conditions that do not change during the simulations.  The model 
comprises 23 ordinary differential equations and 2 algebraic equations.  Dotted lines indicate either activation (+) or inhibition (–).
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There has been particular interest in kinase inhibitors 
[11], anti-oxidants [12], and down-regulation of Mcl-1 
[13, 14]. An example of this last approach is the use of the 
cyclin-dependent kinase inhibitor, seliciclib, also known 
as R-roscovitine and CYC202 [13, 15]. Seliciclib is an 
inhibitor of cdk9, which phosphorylates and activates 
the C-terminal domain of RNA polymerase II [16]. This 
phosphorylation is required for efficient transcription, 
and its inhibition by seliciclib decreases many transcripts. 
However, when transcription ceases, the proteins that 
decline first are those that turn over most rapidly, one 
of which is Mcl-1. Seliciclib caused the decline of Mcl-
1 within 90 minutes, its almost complete disappearance 
within 3 hours, and continuing absence still at 24 hours 
[17].
The kinetics of signalling pathways are complicated by 
multiple positive and negative feedback loops, cross-talk 
between the different pathways, action across multiple 
intracellular compartments, and oscillatory dynamics. 
Understanding these complex kinetics has been facilitated 
by constructing computer models of signalling networks 
[18, 19]. We here describe a model of c-Abl signalling in 
neutrophils.  The approach adopted has been to build upon 
earlier models of myeloid cell maturation [20] by adding 
elements of the c-Abl signalling pathway, including all 
the processes shown in figures 1 and 2. Other published 
models that have guided aspects of our model design are 
those of Zhuge et al.[21], Brookes et al. [22] and Scholz et 
al. [23]. Our model could serve as a tool for exploring the 
comparative activity of different therapeutic approaches, 
to explore potential synthetic lethalities resulting from 
c-Abl activation, and to design optimal drug combination 
protocols.
Figure 2. The two-pronged effect of c-Abl activation. See notes to figure 1.
Methods
Description of the myeloN Model
The scope of the model is shown in Figures 1 and 2. 
Bone marrow stem cells and myeloid progenitor cells 
are able to replicate. They remain localised in bone 
marrow. Neutrophils and monocytes do not replicate. 
The equations of the model are set out in the program 
listing (supplementary material).  The system is basically 
a Bayesian prior belief model that is valid to the extent 
that it produces reasonable responses.
Control mechanisms of the model
1. The proliferating population of myeloid progenitor 
cells has a kinetic reserve of G0 cells. These cells can 
be brought back into cycle in response to depletion 
of the total proliferating compartment, e.g. after 
myelosuppressive chemotherapy (37). 
2. GM-CSF is increased when the number of circulating 
neutrophils is low (e.g. after chemotherapy). The 
model treats this as binding of GM-CSF by circulating 
neutrophils (in which it has no effect), thus lowering 
the steady-state level of GM-CSF. This is a major 
homeostatic mechanism.
3. Interleukin 8 is stimulated by lipopolysaccharide (LPS), 
e.g. after infection, resulting in increased trafficking 
of neutrophils from blood into tissues. Infection also 
causes increased TNFα.
4. c-Abl is activated by TNFα resulting from infection 
or inflammation. c-Abl then phosphorylates STAT5 
and causes neutrophil activation by up-regulation 
of Mcl-1 and Bcl-x. These proteins are inhibitors of 
apoptosis.
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5. Interferon-α phosphorylates and dimerises STAT5, 
which drives transcription of ICSBP, which represses 
transcription of anti-apoptotic proteins.
6. c-Abl activates production of IL-3 and GM-CSF.
Sites of drug action
Nine of the rate processes are subject to inhibition by 
drugs. The drug effects that are modelled are: (1) DNA 
cross-linking, which inhibits cell proliferation (e.g. 
busulphan); (2) Inhibition of GM-CSF (e.g. MOR103); 
(3) Inhibitors of c-Abl tyrosine kinase (e.g. imatinib); 
(4) inhibition of CXCR1 and CXCR2 cytokine receptors 
(e.g. SB272844); (5) DNA synthesis inhibitors (e.g. 
cytarabine); (6) Inhibitors of Mcl-1 transcription (e.g. 
seliciclib); (7) TNFα antagonists (e.g. infliximab); (8) 
Induction of ICSB transcription (e.g. α-interferon); (9) 
Anti-oxidants (e.g. ascorbate).  Currently, only constant 
concentrations of drugs and cytokines are modelled.
Modelling infection
Infection is treated as an instantaneous event occurring at 
zero time.  LPS, a bacterial cell wall component, induces 
a range of cytokines. IL-3, IL-8 and TNFα are explicitly 
simulated by the model. G-CSF, which is produced by 
activated macrophages, is also modelled. IL-8 then triggers 
migration of neutrophils from plasma into the infected 
tissue, while TNFα activates c-Abl. c-Abl stimulates the 
release of ROS from the mitochondrial electron transport 
chain.  Other ROS sources were not modelled, though 
they could be. Regardless of their source, ROS interact 
with myeloperoxidase to release hypochlorite, which is 
bactericidal. The model then assumes that bacteria are 
destroyed by ROS, and that this effect follows a Hill 
equation. The saturation function given by the Hill equation 
is interpreted as a fraction of the maximum antibacterial 
effect, expressed as log kill per hour:
bk = bkmax * ROSn / (K
m
 + ROSn).
Then the bacterial count at time t + dt = bacteriat / 
(10bk*dt). LPS, IL8 and TNFα change in proportion with 
the bacterial count.
Modelling inflammation
Inflammation, specifically COPD, is modelled by 
assuming a constant level of TNFα, which results in 
permanent activation of c-Abl. Only cells in the tissue are 
affected, and no c-Abl activation is assumed in blood or 
bone marrow. 
Programming
The model is implemented in the programming language 
R [38]. Ordinary differential equations are solved using 
the R package deSolve. The equations of the model are 
included in the supplementary material and the program 
listing may be obtained from an R package called myelo 
that we are developing on github to house myelopoiesis-
related models; see http://epbi-radivot.cwru.edu/myelo/
myelo.html for installation directions and once installed, 
see the help page of the function rcj12() which provides 
the right hand side of the model’s differential equations 
used by deSolve. 
Parameter values are listed in the supplementary material. 
Parameter estimates are based upon literature data [1, 2, 
4, 7-9, 13-16, 19-23]. Initial conditions were chosen to 
represent cell numbers in either the unstimulated steady 
state or, for simulation of anti-inflammatory drug effects, 
the untreated inflamed state in presence of activated 
macrophages.
Results
To demonstrate that the model predicted reasonable 
values in the absence of infection, inflammation, or drugs, 
we first simulated the unperturbed steady-state.  Using the 
default starting conditions, with no activation of c-Abl, the 
system was stable (see supplementary material). Output 
from selected simulations is shown in the main text, and 
all simulations are summarized in the supplementary 
material. The modelled circulating neutrophil count was 
about 4.6 million/ml blood, and the steady-state count 
of tissue-infiltrating neutrophils was 75,000/gm tissue. 
Only 0.1% of these were activated in the absence of 
c-Abl stimulation.  The calculated mean residence time 
of neutrophils in plasma was 4.7 days. A low steady state 
level of ROS was well within the capacity of neutrophil 
glutathione peroxidase to remove [24]. Units of cycling 
progenitor cells and of G0 progenitor cells are cells/gm 
of bone marrow.
Interleukin 8 (IL-8) is produced by tissue macrophages, 
which are activated in the presence of bacterial or fungal 
infection, or inflammation. In the absence of infection or 
immune stimulation, tissue levels of IL-8 are very low. 
Simulation 2 modelled the effect of continuous exposure 
to a high concentration (50 nM) of IL-8. This treatment 
resulted in an increase in tissue neutrophils of about 2.6-
fold, peaking at about 22 hours. An increase in activated 
tissue neutrophils was also predicted, of about 2.4-fold, 
peaking at 36 hr. There was a marked decline in the blood 
neutrophil count, correlating with the migration of these 
cells into tissues. The decreased blood neutrophil count 
triggered an increased proliferation of progenitor cells, 
which in turn began to restore the blood neutrophil count. 
ROS increased by about 2-fold, reflecting the increase in 
activated tissue neutrophils.
After treatment for 9 days with a maximum tolerated 
concentration of the interleukin 8 antagonist, SB272844, 
tissue neutrophils reached a nadir of 11% of the normal 
value. Circulating neutrophils increased (simulation 3). 
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The level of ROS production decreased to about 50% 
control. These predictions are consistent with the IL-8 
antagonist’s mechanism of inhibiting trafficking of 
neutrophils from blood into tissues.
A subsequent study (simulation 4) modelled the effect 
of IL-8 (50 nM) in presence of its antagonist, SB272844 
(5 μM). As seen by comparing simulation 4 with 
simulation 3, the increase in tissue neutrophils caused by 
IL-8 was completely prevented. No increase in activated 
neutrophils was seen, in contrast to the 2.4-fold increase 
predicted in absence of SB272844. The increase in ROS 
driven by IL-8 was also completely blocked.
MOR103 is a monoclonal antibody that binds to GM-
CSF and thus prevents its interaction with the GM-CSF 
receptor [25].  It is under clinical evaluation for treatment 
of rheumatoid arthritis, a disease where tissue damage is 
caused by invasion of activated neutrophils.  Simulation 
5 modelled the effect of 10 nM MOR103. Note the rapid 
depletion of myeloid progenitor cells (labelled “CFU-
GM” in the corresponding table of the supplement). The 
model predicted a decrease of 74% in activated neutrophils 
over 10 days.
Simulation 6 examined the effect of increasing 
G-CSF to 5-fold the normal level. Over the first few 
days of treatment the model predicted an 11% increase in 
circulating neutrophils, coupled with a 46% decrease in 
myeloid progenitor cells. This relatively muted response 
presumably reflects the strong homeostatic regulation of 
circulating neutrophils, which cause feedback inhibition 
of the proliferation of progenitor cells [21]. A more marked 
effect was predicted for increasing the level of GM-CSF 
to 12.5x the normal value for 12 days (simulation 7). 
Myeloid progenitor cells increased 3.9-fold by 12 days, 
and circulating neutrophils increased 2.6-fold. Tissue 
neutrophils increased 2.2-fold. The cytokinetic reserve of 
G0 progenitor cells was predicted to show a small relative 
increase from 8% to 9.3% under these conditions.
In simulation 8, a bacterial infection (106 cells/
gm tissue) is assumed to result in the presence of 
lipo-polysaccharide (LPS) in tissues. This activates 
macrophages, which release TNFα, and activation of 
c-Abl results. This causes a strong antibacterial response. 
By ten days, 99.9%+ (5.9 logs) of the bacteria have been 
eliminated, and the ROS level (which peaks at 84 h) is 
returning to normal. Following an initial dip in circulating 
neutrophils, as they migrate into the infected tissues, a 
moderate leucocytosis is seen, with circulating neutrophils 
peaking at 255% normal at 184 h.
The antibacterial response was dependent on the size 
of the bacterial challenge. Simulation 9 shows a bacterial 
challenge of 105 cells/gm tissue. By 10 days, the bacteria 
were completely eliminated. ROS peaked at 6.0x control 
at 60 h. Circulating neutrophils increased 21%, peaking at 
240 h. After a very large bacterial challenge of 107 cells/
gm tissue (simulation 10), ROS reached levels almost 50x 
baseline. Bacterial kill was about 6 logs, and circulating 
neutrophils peaked at 6.5-fold control, at 230 h. At these 
high levels of ROS accumulation, the redox buffer system 
of the cell is saturated, and significant amounts of oxidised 
glutathione appear.
In bacterial infection, the activation of c-Abl is driven, 
indirectly, by bacterial cell wall LPS. As the infection is 
eliminated, production of ROS tapers off. The antibacterial 
response is self-limited, so that oxidative damage to 
host tissues is minimal. The situation is different in 
inflammatory disease, where inflammatory cytokines, 
including TNFα, are produced continually, so that c-Abl 
is permanently activated. We modelled this situation by 
setting TNFα to a constant level of 5 nM (simulation 
11). This resulted in c-Abl activation (0 – 6.34 in 48 h), 
activation of tissue neutrophils (5.6-fold in 48 h), Mcl-1 
(7.1-fold), and ROS (3.8-fold, and still rising at 48 h). ROS 
production eventually levelled off at more than 50-fold 
the baseline value, a level likely to cause significant tissue 
damage. Circulating neutrophils increased moderately 
(40% at 48 h), and tissue neutrophils increased 61%, 
presumably because of decreased apoptosis. This situation 
may be regarded as a first approximation model of COPD, 
for the purposes of in silico drug screening.
If the primary cause of neutrophil activation in COPD 
is TNFα, one way to prevent c-Abl activation may be to 
treat with the anti-TNF antibody, infliximab. Simulation 
12 summarises the result of simultaneous administration 
of TNFα and infliximab. Infliximab (5 nM) inhibited the 
response to TNFα, decreasing the effect on neutrophil 
activation by 81% at 48 h, the effect on ROS by 75%, and 
the effect on Mcl-1 by 83%.
There have been several studies of the effects of 
antioxidants, including ascorbate, on COPD, with some 
preliminary, but encouraging, results on biomarkers of 
oxidative stress [7-10]. The myeloN model assumes, as a 
default value, that human plasma contains 7 mM ascorbate. 
Simulation 13 calculated the baseline ROS production 
in complete absence of anti-oxidants, and simulation 
14 calculated ROS production at 7 mM ascorbate. ROS 
production at this mean physiological level was 74% of 
the value in absence of anti-oxidants, showing only a 
modest protective effect. Increasing ascorbate to 30 mM 
(a concentration that can be achieved by taking very high 
doses of oral ascorbic acid) decreased ROS production 
by 56% (simulation 15). A more relevant question is the 
extent to which high doses of ascorbate can decrease the 
greatly elevated levels of ROS found in COPD. Simulation 
16 allows the ROS production to reach 95% of its steady-
state value after addition of 5 nM TNFα, then adds 30 
mM ascorbate at 480 h. ROS production fell by 75%, but 
was still ten-fold higher than the normal level, suggesting 
that more powerful antioxidants might be beneficial for 
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treatment of COPD.
Because of evidence that the primary factor involved 
in neutrophil activation is the anti-apoptotic protein Mcl-
1 [14], there has been interest in inhibition or down-
regulation of Mcl-1 as an approach to treatment of COPD. 
The Mcl-1 protein and its mRNA both have short turnover 
times, so inhibition of protein synthesis, or inhibition of 
transcription of mRNA, although not inherently selective, 
can cause a disproportionate decrease in Mcl-1. Inhibitors 
of cdk9, such as seliciclib [16, 17] inhibit transcription 
by blocking phosphorylation of the C-terminal domain 
of RNA polymerase II. Seliciclib has shown activity in 
several animal models of inflammatory disease, including 
inflammatory lung disease [13-15]. Simulation 17 
modelled the effect of a constant concentration of 5 μM 
seliciclib on a model of COPD in which c-Abl is kept 
activated by chronic exposure to 0.5 nM TNFα.  Mcl-1 
was down-regulated by 94%, and this was accompanied 
by an 83% decrease in the number of activated neutrophils 
and a 70% decrease in ROS. Seliciclib was predicted to 
have a moderately neutropenic effect, but this was much 
less than its effect on ROS. Modelling the seliciclib 
dose-response relationship showed that ROS could be 
inhibited by up to 87%, but circulating neutrophils did not 
drop below 50% of control, even at very high seliciclib 
concentrations (Figure 3).
Chronic myeloid leukaemia, CML, is a form of 
leukaemia in which a t(9:22) chromosomal translocation 
produces a fusion protein in which a c-Abl domain is fused 
to the protein product of the Bcr gene, and as a result the 
Abl domain is constitutively activated [26-28]. The Bcr-
Abl kinase inhibitor, imatinib (Glivec®) has been used 
very successfully to treat CML [29, 30]. Imatinib and its 
Figure 3. Dose-response curve for the effect of seliciclib on ROS and circulating 
neutrophils. The myeloN model was used to simulate effects of seliciclib concentrations 
of 0.3 to 100 μM on the steady state.
analogues do not appear to distinguish between the Bcr-
Abl kinase domain and that of normal c-Abl, suggesting 
that imatinib could be used to treat COPD. There are no 
published reports of imatinib being used to treat COPD, 
though other kinase inhibitors have been explored for 
this indication [11]. Simulation 18 attempted to predict 
the effect of a high concentration (300 nM) of imatinib 
on COPD. The level of ROS was decreased by 90%. The 
tissue count of activated neutrophils was decreased by 
93%, and Mcl-1 activity was lowered 65%.
The fact that both imatinib and seliciclib were predicted 
to have strong activity against COPD, and by different 
mechanisms, suggested that it would be interesting to 
predict the efficacy of combinations of the two agents. 
The myeloN model was used to simulate effects of 
combinations of imatinib (at concentrations ranging from 
10 – 120 nM) and seliciclib (0.3 – 70 μM). Results were 
analysed by fitting the three-dimensional dose-response 
surface to the equation of Greco et al. [31]. This equation 
describes the response of the system to each drug as a 
Hill function, and includes an additional interaction 
parameter, α. If α = 0, the two agents are additive; α < 0 
implies antagonism, and α > 0 indicates synergism. The 
Greco equation thus describes the degree of inhibition of a 
system in presence of two drugs in terms of 5 parameters: 
IC
50
 and slope of the dose-response curve for each drug 
individually, and α. In descriptions of inhibition kinetics, 
it is conventional to describe the amount of inhibition as 
fraction affected (fa), e.g. for a system that is 35% inhibited, 
fa = 0.35. The fraction unaffected, fu, is then given by fu = 
1 – fa. For the combination of imatinib + seliciclib, using 
ROS as endpoint, the myeloN model predicted an α value 
of 3.70, corresponding to moderate synergy. Presenting 
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the interaction as an isobol plot (Figure 4) shows the 
concave shape characteristic of a synergistic interaction. 
Isobols show the degree of drug interaction at levels 
required to produce a fixed endpoint – in this case an IC
50
.
Figure 5 shows the drug interaction as a 3-dimensional 
response surface. This form of data presentation has the 
advantage that it covers the entire range of concentrations 
for both drugs. The complex shape of this plot reflects 
the fact that the slope of the Hill function for imatinib is 
much steeper than for seliciclib, creating an asymmetry in 
the shape of the surface. The R programming language, 
which was used to plot this figure, makes it possible to 
rotate the diagram on a computer screen, giving a better 
impression of the details of the response surface.
Another popular method of depicting drug interaction 
data is the median effect plot of Chou and Talalay [32]. 
This method measures the effect of mixtures of the two 
drugs, at various concentrations, but at a fixed ratio.  The 
sum of the amounts of each drug, as a fraction of its median 
effective dose, is termed the combination index (CI). For 
example, if achieving 50% inhibition of a system by a 
combination of two drugs required 50% of the IC
50
 level of 
the first drug and 70% of the IC
50
 level of the second drug, 
then CI = 0.5 + 0.7 = 1.2. Unlike Greco’s alpha parameter, 
Figure 4. Isobol plot for the imatinib + seliciclib combination. The diagonal shows 
the line of additivity. The concave shape of the isobol indicates synergy; the lines 
above and below the isobol are the upper and lower 95% confidence intervals.
Figure 5. 3-Dimensional response surface for the imatinib + seliciclib combination. 
Arrows on the x and y axes indicate directions of increasing drug concentration. 
fu = fraction unaffected.
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CI is not constant over the concentration range, but varies 
with the degree of inhibition. Values of CI = 1 correspond 
to additivity, CI > 1 corresponds to antagonism, and CI 
< 1 to synergism. Figure 6 shows CI versus fa (fraction 
affected) for the imatinib + seliciclib combination. The 
combination was predicted to be synergistic over most of 
the concentration range, and approximately additive at 
high degrees of inhibition.
The combination of seliciclib and ascorbate was also 
modelled, using inhibition of ROS as endpoint. The 
calculated alpha parameter was -0.023, not significantly 
Figure 6. Combination index values for the imatinib + seliciclib combination. 
Predicted values of ROS calculated by the myeloN program were analysed by the 
method of Chou and Talalay [32].
different from zero, indicating an additive interaction. 
The isobol plot for this combination is shown in Figure 7.
Finally, the myeloN program was used to model 
the interaction between seliciclib and SB272844. The 
rationale for this combination was that seliciclib triggers 
apoptosis of activated neutrophils, whereas SB272844 
blocks trafficking of circulating neutrophils into tissues. 
Simulation 19 shows the effect of 1.34 μM seliciclib. 
Based upon the value of ROS at 480 h, the degree of 
inhibition is 50.0%, i.e. the fraction unaffected (fu) = 0.5.
Simulation 20 shows the effect of 2.43 μM SB272844. 
Figure 7. Isobol plot for the ascorbate + seliciclib combination. The diagonal shows 
the line of additivity.  The isobol line overlays the additivity line, indicating that the 
combination does not differ significantly from additivity.
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Over 480 h, this treatment reduces leakage of ROS by 
50%, i.e. fu = 0.5. Simulation 21 shows the combined 
effect of 1.34 μM seliciclib plus 2.43 μM SB272844. 
ROS leakage is inhibited by 87.6% by 480 h, i.e. fu = 
0.124. If the two drugs act independently, as defined by 
Bliss [32], the fraction unaffected by the combination 
would be 0.5 x 0.5 = 0.25. Since the actual value is 
less than half of this, the combination is synergistic, as 
defined by Bliss. Using the response surface approach of 
Greco et al. [31,33] gave an alpha value of 8.72 (95% 
CL 6.58 – 12.21) corresponding to strong synergism. 
The isobol for the combination is shown in Figure 8, 
and is markedly concave. These predictions suggest 
that the combination of a drug that down-regulates Mcl-
1 with a drug that inhibits neutrophil trafficking merits 
experimental evaluation.
Figure 8. Isobol plot for the SB272844 + seliciclib combination. The diagonal shows 
the line of additivity.  The concave shape of the isobol indicates synergy.
Discussion
The myeloN model captures the key qualitative features 
of neutrophil trafficking and activation, and of the 
response of these processes to infection and inflammation. 
cAbl appears to act as the primary control point for 
neutrophil activation, and in turn, through its effect on 
STAT transcription factors, activates multiple pathways. 
We have chosen to describe two of these in detail: the 
STAT5-mediated up-regulation of Mcl-1, which turns the 
normally transient tissue neutrophils into a much more 
long-lived cell population. Secondly, our model describes 
ROS production following neutrophil activation. This 
effect is driven by STAT3. Such ROS can arise from 
mitochondria, peroxisomes, or NADPH oxidase in the 
plasma membrane. In this paper we let mitochondrial 
ROS represent all three possible sources. ROS mediate the 
primary bactericidal function of neutrophils, but if they 
persist too long, they can cause serious oxidative damage 
to normal tissues.  This tissue damage is a primary cause 
of morbidity in COPD and other inflammatory diseases. 
A gatekeeper role of c-Abl is supported by the 
fact that its permanent activation results in malignant 
transformation. The Abelson murine leukaemia virus 
transforms murine lymphoblasts by expressing a 
constitutively activated form of the gene, v-Abl [34]. In 
humans, chronic myeloid leukaemia (CML) is caused by 
a chromosomal translocation that results in a fusion gene, 
Bcr-Abl, whose Abl domain is constitutively active [26]. 
These oncogenic forms of the Abelson gene appear to 
be sufficient for transformation. An inhibitor of the Abl 
domain of Bcr-Abl, imatinib, gives high response rates, 
and long response durations in CML [29], reinforcing the 
critical role of the Abelson gene in neutrophil function.
The aetiology of COPD is complex, but there is 
general agreement that production of inflammatory 
cytokines, stimulated by inhaled irritants such as tobacco 
smoke, is the primary cause. The tissue injury caused by 
COPD is attributable to oxidative damage, and it has been 
suggested that ROS present in tobacco smoke, as well as 
ROS produced by activated neutrophils, are responsible. 
ROS are equally harmful, regardless of their source, and 
it is likely that anti-oxidants may be beneficial whatever 
the source of the ROS. However, abnormally high ROS 
production persists long after cessation of smoking, and 
in such cases, at least, the primary source must be internal 
rather than external. Our computational model of COPD 
assumes that c-Abl is chronically activated, and this single 
factor is predicted to lead to all the other consequences: 
abnormally high numbers of tissue neutrophils, persistent 
BioDiscovery | www.biodiscoveryjournal.co.uk March 2013 | Issue 7 | 410
Modelling c-Abl signalling
activation of tissue neutrophils, elevated production of 
the anti-apoptotic protein Mcl-1, inhibition of neutrophil 
apoptosis, very high levels of ROS, represented here 
by electron leakage from the mitochondrial ETC, and 
resulting tissue injury.
The branched signalling pathway downstream from 
Bcr-Abl has interesting implications for the treatment of 
COPD.  Since the damage to lung tissue in this disease is 
caused by ROS, it is reasonable to expect that antioxidants 
should have activity in this disease, and indeed the 
model predicts that this will be the case. However, the 
antioxidant effect, though providing symptomatic relief, 
does not address the causes of the problem, the continued 
activation of tissue neutrophils.  Imatinib and seliciclib 
do cause depletion of activated tissue neutrophils, and the 
model predicts that they will be effective treatments for 
COPD. However, their effect is somewhat delayed, as the 
reactivation of apoptosis takes a few days to deplete the 
activated neutrophil population. Perhaps a combination 
of the two approaches will be superior to either used 
separately. The model suggests that the combined effects of 
ascorbate and seliciclib should be additive.  Interestingly, 
the most striking synergy was predicted to result from 
the simultaneous triggering of tissue neutrophil apoptosis 
with seliciclib, and prevention of neutrophil trafficking 
from plasma into lung tissue, with SB272844.
The myeloN model thus provides a tool for rapid 
prediction of effective sites for drug intervention in 
COPD and other neutrophil-driven inflammatory 
conditions. Of course its predictions must be subjected 
to experimental verification, but the ability to explore a 
large number of possibilities in silico makes it possible to 
prioritise scarce experimental resources for those targets 
and drugs most likely to be successful. This is particularly 
the case for devising effective combination protocols. 
This is an inherently combinatorial problem, especially 
when multiple drugs, multiple dose levels, sequence-
dependent effects and varying degrees of drug selectivity 
are involved. Based upon the nine sites for inhibition 
included in the myeloN model, there are (9 x 8)/2! = 36 
mechanistically distinct binary inhibitor combinations. 
Of these, we have so far only explored three, of which one 
was predicted to be moderately synergistic, one additive, 
and one highly synergistic. In future studies we plan to 
explore the remaining 33 binary combinations and the 
(9 x 8 x 7)/3! = 84 possible three-drug combinations.
In some therapeutic areas, such as oncology [35] and 
cardiovascular disease [36] complex pharmacodynamic 
modelling has provided a tool for planning biomarker 
strategy – which biomarkers will correlate best with 
clinical outcome, which sampling strategy will have 
the greatest information content. The myeloN model of 
c-Abl signalling in COPD may be useful in identifying 
biomarkers of oxidative damage, and the effects of anti-
oxidants that can guide the design of clinical use of anti-
oxidants.
The myeloN model, in its present form, is a PD model: 
it relates drug concentrations to a PD effect. As such, it 
can model the effect of constant drug concentrations, as 
in in vitro experiments. To describe in vivo drug effects, 
it will be necessary to combine the myeloN model with a 
pharmacokinetic (PK) model that describes how the drug 
distributes within the body, and how its concentration 
changes with time. When validated against in vivo 
experimental data, including biomarker measurements, 
and combined with human PK data, these PK/PD models 
have the potential to be used for in silico clinical trials.
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